Moreover, SETD4 expression correlated positively with the likelihood of disease progression in prostate adenocarcinoma (PRAD), ACC, LIHC, and uveal melanoma (UVM) (Figure 2B). This evidence concerns the gene SETD4 and uveal melanoma.